Transcriptional control of Sost in bone

Journal Article · Wed Mar 01 00:00:00 EST 2017 · Bone

DOI:https://doi.org/10.1016/j.bone.2016.10.009· OSTI ID:1330597

Sebastian, Aimy; Loots, Gabriela G.

Sclerostin is an osteocyte derived negative regulator of bone formation. A highly specific expression pattern and the exclusive bone phenotype have made Sclerostin an attractive target for therapeutic intervention in treating metabolic bone diseases such as osteoporosis and in facilitating fracture repair. Understanding the molecular mechanisms that regulate Sclerostin transcription is of great interest as it may unveil new avenues for therapeutic approaches. Such studies may also elucidate how various signaling pathways intersect to modulate bone metabolism. Furthermore we review the current understanding of the upstream molecular mechanisms that regulate Sost/SOST transcription, in bone.

• Research Organization: Lawrence Livermore National Laboratory (LLNL), Livermore, CA (United States)
• Sponsoring Organization: USDOE
• Grant/Contract Number: 16-ERD-007; AC52-07NA27344
• OSTI ID: 1330597
• Alternate ID(s): OSTI ID: 1347664
• Report Number(s): LLNL-JRNL-691682; S875632821630299X; PII: S875632821630299X
• Journal Information: Bone, Journal Name: Bone Vol. 96 Journal Issue: C; ISSN 8756-3282
• Publisher: Elsevier
• Country of Publication: United States
• Language: English

Related Subjects

59 BASIC BIOLOGICAL SCIENCES